Scholars@Duke
Lake Daniel Morrison

Lake Daniel Morrison

Associate Professor of Medicine
Medicine, Pulmonary, Allergy, and Critical Care Medicine
lake.morrison@duke.edu
Duke Box 102355, Durham, NC 27710
101 Hanes House, Trent Drive, Durham, NC 27710

Selected Publications

Cough-Specific Quality of Life Predicts Disease Progression Among Patients With Interstitial Lung Disease: Data From the Pulmonary Fibrosis Foundation Patient Registry.

Journal Article Chest · September 2022 BackgroundCough is a common symptom of interstitial lung disease (ILD) and negatively impacts health-related quality of life (QOL). Previous studies have shown that among patients with idiopathic pulmonary fibrosis, cough may predict progression o ... Full text Cite

Provider Perspectives on and Access to Palliative Care for Patients With Interstitial Lung Disease.

Conference Chest · August 2022 BackgroundInterstitial lung disease (ILD) results in profound symptom burden and carries high mortality. Palliative care (PC) is dedicated to improving quality of life in patients with serious illness. Early PC provision improves rates of advance ... Full text Cite

Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry.

Conference Ann Am Thorac Soc · June 2022 Rationale: Lung transplant offers the potential to extend life for patients with idiopathic pulmonary fibrosis (IPF); yet, this therapeutic modality is only available to a small proportion of patients. Objectives: To identify clinical characteristics and s ... Full text Link to item Cite

Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry.

Journal Article Lung · February 2022 PURPOSE: To assess the impact of concomitant emphysema on outcomes in patients with idiopathic pulmonary fibrosis (IPF). METHODS: The IPF-PRO Registry is a US registry of patients with IPF. The presence of combined pulmonary fibrosis and emphysema (CPFE) a ... Full text Link to item Cite

Comparison of Forceps, Cryoprobe, and Thoracoscopic Lung Biopsy for the Diagnosis of Interstitial Lung Disease - The CHILL Study.

Journal Article Respiration · 2022 RATIONALE: Transbronchial lung cryobiopsy (TBLC) has emerged as a less invasive method to obtain a tissue diagnosis in patients with interstitial lung disease (ILD). The diagnostic yield of TBLC compared to surgical lung biopsy (SLB) remains uncertain. OBJ ... Full text Link to item Cite

Hyperpolarized 129Xe MRI and Spectroscopy of Gas-Exchange Abnormalities in Nonspecific Interstitial Pneumonia.

Journal Article Radiology · October 2021 Background Recent studies demonstrate that antifibrotic drugs previously reserved for idiopathic pulmonary fibrosis (IPF) may slow progression in other interstitial lung diseases (ILDs), creating an urgent need for tools that can sensitively assess disease ... Full text Link to item Cite

Hospitalizations in patients with idiopathic pulmonary fibrosis.

Journal Article Respir Res · September 30, 2021 BACKGROUND: Hospitalizations are common among patients with idiopathic pulmonary fibrosis (IPF). We investigated the impact of hospitalizations on outcomes in patients with IPF. METHODS: The IPF-PRO Registry is an observational US registry that enrolled pa ... Full text Link to item Cite

Associations between Patient-reported Outcomes and Death or Lung Transplant in Idiopathic Pulmonary Fibrosis. Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry.

Journal Article Ann Am Thorac Soc · June 2020 Rationale: Progression of idiopathic pulmonary fibrosis (IPF) is accompanied by worsening of symptoms, exercise capacity, and health-related quality of life. However, the utility of patient-reported outcomes as predictors of mortality remains uncertain.Obj ... Full text Link to item Cite

Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis: A Cross-Sectional Analysis of the IPF-PRO Registry.

Journal Article Chest · May 2020 BACKGROUND: Limited data are available on the association between clinically measured disease severity markers and quality of life (QOL) in idiopathic pulmonary fibrosis (IPF). The study examined the associations between objective disease severity metrics ... Full text Link to item Cite

Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort.

Journal Article BMC Pulm Med · March 14, 2020 BACKGROUND: Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) play important roles in the turnover of extracellular matrix and in the pathogenesis of idiopathic pulmonary fibrosis (IPF). This study aimed to determine the utility of cir ... Full text Link to item Cite

A Smart-Phrase to Improve Documentation of Supportive Measures for Idiopathic Pulmonary Fibrosis

Journal Article Journal for Nurse Practitioners · February 1, 2020 Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease of unknown cause occurring in adults and affecting approximately 5 million people worldwide. The American Thoracic Society 2015 guidelines provide recommendations for the treatment ... Full text Cite

Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry.

Journal Article Respiratory research · October 2019 BackgroundIdiopathic pulmonary fibrosis (IPF) is a progressive lung disease for which diagnosis and management remain challenging. Defining the circulating proteome in IPF may identify targets for biomarker development. We sought to quantify the c ... Full text Cite

Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry.

Journal Article Respir Res · May 30, 2019 BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a variable clinical course and high mortality. We used data from a large national US registry of patients with IPF to investigate relationships between patient characteristics, i ... Full text Link to item Cite

Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis: Experience from 92 Sites in an Open-Label US Expanded Access Program

Journal Article Pulmonary Therapy · December 1, 2017 Introduction: In phase 3 clinical trials, pirfenidone significantly slowed disease progression with a well-defined and medically manageable safety profile in patients with idiopathic pulmonary fibrosis (IPF). This study examined safety events related to pi ... Full text Cite

2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.

Journal Article Arthritis Care Res (Hoboken) · August 2017 OBJECTIVE: To develop recommendations for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP). METHODS: We conducted a systematic review to synthesize the evidence for the benefits and harms of GIOP prevention and treatment options. The ... Full text Link to item Cite

2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.

Journal Article Arthritis Rheumatol · August 2017 OBJECTIVE: To develop recommendations for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP). METHODS: We conducted a systematic review to synthesize the evidence for the benefits and harms of GIOP prevention and treatment options. The ... Full text Link to item Cite

Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy.

Journal Article Eur Respir J · March 2016 Abnormal fibrogenic repair response upon alveolar injury is believed to play an important role in the pathogenesis of idiopathic pulmonary fibrosis (IPF). PRM-151 (recombinant human pentraxin-2, also known as serum amyloid P), has been shown to reduce fibr ... Full text Link to item Cite

The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet): diagnostic and adjudication processes.

Journal Article Chest · October 2015 BACKGROUND: The National Heart, Lung, and Blood Institute-sponsored IPF Clinical Research Network (IPFnet) studies enrolled subjects with idiopathic pulmonary fibrosis (IPF) to evaluate drug therapies in treatment trials. An adjudication committee (AC) pro ... Full text Link to item Cite

Quantitative proteomics of bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis.

Journal Article J Proteome Res · February 6, 2015 The proteomic analysis of bronchoalveolar lavage fluid (BALF) can give insight into pulmonary disease pathology and response to therapy. Here, we describe the first gel-free quantitative analysis of BALF in idiopathic pulmonary fibrosis (IPF), a chronic an ... Full text Link to item Cite

Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.

Journal Article Respir Med · January 2014 BACKGROUND: Dyspnea is a hallmark symptom of idiopathic pulmonary fibrosis (IPF), and dyspnea induced physical activity limitation is a prominent driver of quality of life impairment among IPF patients. METHODS: We examined response data for the 21 physica ... Full text Link to item Cite

Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.

Journal Article Respir Res · July 13, 2013 BACKGROUND: Acute exacerbation of idiopathic pulmonary fibrosis has become an important outcome measure in clinical trials. This study aimed to explore the concept of suspected acute exacerbation as an outcome measure. METHODS: Three investigators retrospe ... Full text Link to item Cite

Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.

Journal Article Ann Intern Med · May 7, 2013 BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is characterized by formation and proliferation of fibroblast foci. Endothelin-1 induces lung fibroblast proliferation and contractile activity via the endothelin A (ETA) receptor. OBJECTIVE: To determine whe ... Full text Link to item Cite

A Phase I Study Of Prm-151 In Patients With Idiopathic Pulmonary Fibrosis

Conference AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE · January 1, 2013 Link to item Cite

Bayesian probit regression model for the diagnosis of pulmonary fibrosis: proof-of-principle.

Journal Article BMC Med Genomics · October 5, 2011 BACKGROUND: The accurate diagnosis of idiopathic pulmonary fibrosis (IPF) is a major clinical challenge. We developed a model to diagnose IPF by applying Bayesian probit regression (BPR) modelling to gene expression profiles of whole lung tissue. METHODS: ... Full text Link to item Cite

A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.

Journal Article N Engl J Med · August 12, 2010 BACKGROUND: Sildenafil, a phosphodiesterase-5 inhibitor, may preferentially improve blood flow to well-ventilated regions of the lung in patients with advanced idiopathic pulmonary fibrosis, which could result in improvements in gas exchange. We tested the ... Full text Link to item Cite

Longitudinal Changes in Pathological Specimens Obtained from Patients with Chronic Fibrotic Interstitial Pneumonia

Journal Article AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE · January 1, 2009 Link to item Cite

Nonspecific interstitial pneumonia, alveolar proteinosis, and abnormal proprotein trafficking resulting from a spontaneous mutation in the surfactant protein C gene.

Journal Article Pediatr Res · January 2005 Human surfactant protein C (hSP-C(1-197)) is synthesized as a 197 amino acid proprotein and cleaved to a mature 3.7 kD form. Although interstitial lung disease in patients with mutations of the hSP-C gene is becoming increasingly recognized, the mechanisms ... Full text Link to item Cite

Macrophage colony-stimulating factor can modulate immune responses and attract dendritic cells in vivo.

Journal Article Hum Gene Ther · January 20, 2000 Studies have indicated that professional APCs in the periphery, such as dendritic cells and macrophages, play an important role in initiating DNA vaccine-specific immune responses. To engineer the immune response induced by DNA vaccines in vivo we investig ... Full text Link to item Cite

CD86 (B7-2) can function to drive MHC-restricted antigen-specific CTL responses in vivo.

Journal Article J Immunol · March 15, 1999 Activation of T cells requires both TCR-specific ligation by direct contact with peptide Ag-MHC complexes and coligation of the B7 family of ligands through CD28/CTLA-4 on the T cell surface. We recently reported that coadministration of CD86 cDNA along wi ... Link to item Cite

Intracellular adhesion molecule-1 modulates beta-chemokines and directly costimulates T cells in vivo.

Journal Article J Clin Invest · March 1999 The potential roles of adhesion molecules in the expansion of T cell-mediated immune responses in the periphery were examined using DNA immunogen constructs as model antigens. We coimmunized cDNA expression cassettes encoding the adhesion molecules intrace ... Full text Link to item Cite

Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine.

Journal Article Oncogene · December 17, 1998 Nucleic acid immunization has been investigated as immunotherapy for infectious diseases as well as for treating specific types of cancers. In this approach, nucleic acid expression cassettes are directly inoculated into the host, whose transfected cells b ... Full text Link to item Cite

Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes.

Journal Article Vaccine · November 1998 DNA immunization has been investigated as a potential immunization strategy against infectious diseases and cancer. To enhance a DNA vaccine's ability to induce CTL response in vivo, we co-administered CD80 and CD86 expression cassettes along with HIV-1 im ... Full text Link to item Cite

CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines.

Journal Article J Clin Invest · September 15, 1998 The potential roles of CD8(+) T-cell-induced chemokines in the expansion of immune responses were examined using DNA immunogen constructs as model antigens. We coimmunized cDNA expression cassettes encoding the alpha-chemokines IL-8 and SDF-1alpha and the ... Full text Link to item Cite

Coadministration of IL-12 or IL-10 expression cassettes drives immune responses toward a Th1 phenotype.

Journal Article J Interferon Cytokine Res · July 1998 Cytokines are important regulators of the immune response. They influence immune expression, the development of immunologic memory, and regulation of antigen-specific and nonspecific immune activation as well as allergic responses. In a model system in mic ... Full text Link to item Cite

CD86 confers and directs MHC class I restricted CTL induction

Journal Article FASEB Journal · March 20, 1998 The complex process of CTL induction is only partially understood. Activation of T cells requires both TCR-specific ligation by direct contact with peptide antigen-MHC complexes and co-ligation of the B7 family of ligands with CD28/CTLA-4 on the T cell sur ... Cite

Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens.

Journal Article Eur J Immunol · March 1998 Immunization with nucleic acids has been shown to induce both antigen-specific cellular and humoral immune responses in vivo. We hypothesize that immunization with DNA could be enhanced by directing specific immune responses induced by the vaccine based on ... Full text Link to item Cite